Strategies to enhance the therapeutic efficacy, applicability, and safety of genetically engineered immune cells (2021)
- Authors:
- USP affiliated authors: COVAS, DIMAS TADEU - FMRP ; SOUZA, LUCAS EDUARDO BOTELHO DE - FMRP ; LIMA, SARAH CAROLINE GOMES DE - FMRP ; SILVEIRA, ROBERTA MARANINCHI - FMRP ; FURTADO, IZADORA PETER - FMRP ; ROSSETTI, RAFAELA - FMRP ; BRAND, HELOISA - FMRP
- Unidade: FMRP
- DOI: 10.1615/CritRevImmunol.2021037437
- Subjects: TERAPÊUTICA MÉDICA; NEOPLASIAS; GENÉTICA; CÉLULAS-TRONCO; BIOMARCADORES
- Keywords: CAR-T; Cell therapy; TCR; Gene editing; Cancer
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Critical Reviews in Immunology
- ISSN: 1040-8401
- Volume/Número/Paginação/Ano: v. 41, n. 1, p. 41-67, 2021
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
LIMA, Sarah Caroline Gomes de et al. Strategies to enhance the therapeutic efficacy, applicability, and safety of genetically engineered immune cells. Critical Reviews in Immunology, v. 41, n. 1, p. 41-67, 2021Tradução . . Disponível em: https://doi.org/10.1615/CritRevImmunol.2021037437. Acesso em: 02 dez. 2025. -
APA
Lima, S. C. G. de, Fantacini, D. M. C., Batista, L. de C., Silveira, R. M., Furtado, I. P., Rossetti, R., et al. (2021). Strategies to enhance the therapeutic efficacy, applicability, and safety of genetically engineered immune cells. Critical Reviews in Immunology, 41( 1), 41-67. doi:10.1615/CritRevImmunol.2021037437 -
NLM
Lima SCG de, Fantacini DMC, Batista L de C, Silveira RM, Furtado IP, Rossetti R, Brand H, Covas DT, Souza LEB de. Strategies to enhance the therapeutic efficacy, applicability, and safety of genetically engineered immune cells [Internet]. Critical Reviews in Immunology. 2021 ; 41( 1): 41-67.[citado 2025 dez. 02 ] Available from: https://doi.org/10.1615/CritRevImmunol.2021037437 -
Vancouver
Lima SCG de, Fantacini DMC, Batista L de C, Silveira RM, Furtado IP, Rossetti R, Brand H, Covas DT, Souza LEB de. Strategies to enhance the therapeutic efficacy, applicability, and safety of genetically engineered immune cells [Internet]. Critical Reviews in Immunology. 2021 ; 41( 1): 41-67.[citado 2025 dez. 02 ] Available from: https://doi.org/10.1615/CritRevImmunol.2021037437 - Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer
- Genome editing for engineering the next generation of advanced immune cell therapies
- Optimization of a process for high-yield lentiviral vector production applied to car-t cell generation
- Desenvolvimento de uma nova imunoterapia para tumores sólidos utilizando linfócitos T modificados geneticamente para expressar um TCR projetado anti-NY-ESO-1
- Successful use of human AB serum to support the expansion of adipose tissue-derived mesenchymal stem/stromal cell in a microcarrier-based platform
- Development of a platform for tracking CAR-T cell persistence using qPCR and multiparametric flow cytometry for preclinical and clinical studies
- Localização subcelular do vírus da Zika durante a infecção em células humanas
- Human pegivirus-1 (HPgV-1, GBV-C) RNA prevalence and genotype diversity among volunteer blood donors from an intra-hospital hemotherapy service in Southern Brazil
- Human pegivirus-1 (HPgV-1) RNA prevalence and genotypes in volunteer blood donors from the Brazilian Amazon
- Molecular prevalence and genotypes of human pegivirus-1 (HPgV-1) and SENV-like viruses among multiply transfused patients with beta-thalassemia
Informações sobre o DOI: 10.1615/CritRevImmunol.2021037437 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003201701.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
